Clinical Trial Update: A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Irosustat as an endocrine therapy for breast cancer to slow tumor growth was terminated. The study was sponsored by Imperial College …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Irosustat (irosustat)

Snippet

Sponsor: Imperial College London | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED